<DOC>
	<DOCNO>NCT02385994</DOCNO>
	<brief_summary>The purpose investigation evaluate safety efficacy Cutera enlighten dual-pulse duration , dual-wavelength 532nm KTP/1064nm Nd : YAG laser treatment melasma lentigo face Asian skin .</brief_summary>
	<brief_title>A Prospective Multi-Center Study Using Laser Treatment Melasma Lentigines Asian Skin</brief_title>
	<detailed_description>This multi-center prospective , 2 cohort study 80 male female subject Asian-descent , desire laser treatment moderate severe melasma ( type ) lentigo ( type ) locate face . Forty subject enrol cohort 1 randomize either treatment control arm . Forty subject enrol treatment facial lentigo cohort 2 .</detailed_description>
	<mesh_term>Melanosis</mesh_term>
	<mesh_term>Lentigo</mesh_term>
	<criteria>Female Male , 20 75 year age ( inclusive ) . Fitzpatrick Skin Type III V. Has moderate severe melasma ( type ) , OR type lentigo/lentigines â‰¥ 6mm diameter , desire laser treatment . Willing refrain use topical systemic corticosteroid retinoids , topical systemic prescription skinlightening medication , except permitted topical steroid use direct study doctor . Willing maintain consistent skin care regimen treatment area duration study , include followup period . Must able read , understand sign Informed Consent Form . Must willing able adhere treatment followup schedule posttreatment care instruction . Willing limited sun exposure use approve sunscreen SPF 50 high treatment area every day duration study , include followup period . Willing digital photograph take treatment area . Agree undergo procedure ( ) treatment area study . Postmenopausal surgically sterilize , use medically acceptable form birth control least 3 month prior enrollment entire course study . Participation clinical trial another device drug within 6 month prior enrollment study . Any type prior cosmetic treatment target area within 6 month study participation , laser lightbased procedure surgery . Prior injection collagen , hyaluronic acid filler dermal filler target area within 6 month study participation . Has mild melasma OR facial lentigo/lentigines less 6mm diameter . History refractory melasma . History allergy local anesthetic , applicable . History malignant tumor target area . Skin abnormalities target area , e.g. , cut , scrape , wound . Pregnant and/or breastfeeding . Having infection , dermatitis rash treatment area . Significant concurrent illness , diabetes mellitus cardiovascular disease , e.g. , uncontrolled hypertension . Suffering coagulation disorder take prescription anticoagulation medication . History keloid scarring , hypertrophic scar abnormal wound healing . History immunosuppression/immune deficiency disorder currently use immunosuppressive medication . History vitiligo , eczema , psoriasis . History connective tissue disease , systemic lupus erythematosus scleroderma . History seizure disorder due light . Any use medication know increase sensitivity light accord Investigator 's discretion . History disease stimulate heat , recurrent herpes simplex and/or herpes zoster ( shingle ) treatment area , unless treatment conduct follow prophylactic regimen . History radiation treatment area undergo systemic chemotherapy treatment cancer . History hormone treatment , estrogen , progesterone and/or oral contraceptive , initiate within 3 month study participation , plan discontinue hormone therapy study , applicable . Systemic use prescription skinlightening agent ( tranexamic acid ) , isotretinoin ( retinoid ) , photosensitize medication , corticosteroid within 6 month study participation , except subject undergoes 6month washout period exclude systemic prescription prior first laser treatment . Topical use prescription skinlightening agent ( hydroquinone ) , isotretinoin ( retinoid ) , photosensitize medication , corticosteroid treatment area within 6 month study participation , except permitted topical steroid use direct study doctor subject undergo 6month washout period exclude topical prescription prior first laser treatment . Anytime life , use gold therapy ( gold salt ) disorder rheumatologic disease lupus . Excessively tanned area treat unable/unlikely refrain tan study . As per Investigator 's discretion , physical mental condition might make unsafe subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>